Trial Profile
A Single-Center, Double-Blinded, Placebo-Controlled, Phase 1 Evaluation of the Safety of Ragweed Mix Given in Four Monthly Doses by Intralymphatic Node Injections for Inducing Tolerance in Subjects With Ragweed Induced Allergic Conjunctivitis and Allergic Rhinitis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Ragweed allergy immunotherapy (Primary)
- Indications Allergic conjunctivitis; Allergic rhinitis
- Focus Adverse reactions
- Sponsors Woodmont Pharmaceuticals
- 21 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Mar 2017 Status changed from not yet recruiting to recruiting.